What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

Why It Matters

By curtailing 503B compounding, the FDA safeguards the pricing power and supply control of Lilly’s and Novo’s blockbuster GLP‑1 drugs, reinforcing their dominance in the fast‑growing weight‑loss market.

Key Takeaways

• FDA proposal removes 503B compounding of tirzepatide and semaglutide.
• Lilly’s Q1 revenue grew 56% YoY, guiding 28% full‑year growth.
• Novo expects 5‑13% constant‑currency sales decline in 2026.
• Lilly shares rose ~10% and Novo up ~5% after news.
• Hims’ Novo partnership limits future compounding competition.

Pulse Analysis

The GLP‑1 class has reshaped the weight‑loss and diabetes landscape, with Eli Lilly’s tirzepatide (Mounjaro/Zepbound) delivering roughly 47% greater weight loss than Novo Nordisk’s semaglutide. Lilly’s aggressive market capture has driven a 56% year‑over‑year revenue jump this quarter and a projected 28% full‑year growth, while Novo, once the clear leader, now anticipates a 5‑13% sales dip in 2026. This divergence underscores how product efficacy, pricing, and supply chain control can rapidly shift market leadership in a high‑growth therapeutic segment.

The FDA’s draft rule to exclude tirzepatide and semaglutide from the 503B bulk‑drug list targets a niche but growing compounding ecosystem that emerged during the 2022 shortages. By preventing outsourcing facilities from producing compounded versions, the agency aims to eliminate a parallel supply channel that siphons demand from the originators. Investors rewarded both manufacturers—Lilly’s shares jumped nearly 10% and Novo’s rose almost 5%—signaling confidence that the move will protect margins and reduce price‑erosion pressure from lower‑cost compounded alternatives.

For telehealth players like Hims & Hers, the proposal presents a mixed bag. The firm already secures a branded semaglutide agreement with Novo, insulating it from the loss of 503B competitors, while its relationship with Lilly remains indirect. As a result, Hims can continue to attract patients seeking GLP‑1 therapies without fearing a flood of cheaper compounded options. The broader implication is a more consolidated GLP‑1 market, where regulatory clarity reinforces the dominance of the two manufacturers and forces compounding businesses to pivot or exit, potentially reshaping the telehealth distribution model for specialty drugs.